NCT03616886 - Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC | Biotech Hunter

Enrollment

129

Participants

Timeline

Start Date

December 28, 2018

Primary Completion Date

March 31, 2025

Study Completion Date

December 31, 2025

Conditions

Triple Negative Breast Cancer

Interventions

DRUG

Paclitaxel

Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).

DRUG

Carboplatin

Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).

DRUG

MEDI4736

Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).

DRUG

MEDI9447

Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).

Trial Locations (16)

1000

Institut Jules Bordet, Brussels

5000

CHU UCL Namur Sainte-Elisabeth, Namur

86021

CHU Poitiers, Poitiers

Unknown

Cliniques universitaires Saint Luc, Brussels

Grand Hôpital de Charleroi, Charleroi

UZ Leuven Gasthuisberg, Leuven

Clinique St Pierre, Ottignies

Sint-Augustinus, GZA Ziekenhuizen, Wilrijk

CHU Besançon, Besançon

Institut Bergonié, Bordeaux

Centre Georges François Leclerc, Dijon

Institut Paoli-Calmettes, Marseille

Centre Antoine Lacassagne, Nice

Institut Curie, Paris

Centre Henri Becquerel, Rouen

Hôpitaux Universitaires de Strasbourg, Strasbourg